Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
Novo Nordisk’s liraglutide diabetes brand. It matters mainly because readers often compare it with Saxenda and want to understand the same-molecule, different-label relationship.
FDA-approved for type 2 diabetes, not chronic weight management. Saxenda is the obesity label for liraglutide.
GLP-1 receptor agonist
Generally tied to diabetes coverage rules rather than obesity-benefit design.
GLP-1 receptor agonist
Novo Nordisk’s liraglutide diabetes brand. It matters mainly because readers often compare it with Saxenda and want to understand the same-molecule, different-label relationship.
medication
current
2010
Victoza
liraglutide
Novo Nordisk
No direct U.S. generic brand equivalent.
liraglutide
Branded daily injectable with high cost absent coverage, though it sits outside the current attention peak occupied by semaglutide and tirzepatide brands.
Generally tied to diabetes coverage rules rather than obesity-benefit design.
Useful mainly for readers comparing liraglutide brands and understanding how molecule overlap does not mean interchangeable labeling.
Victoza is now more of a context-setting brand than a center-of-gravity obesity product, but it remains part of the liraglutide story.
Shares the same broad GLP-1 warning themes seen with Saxenda.
nausea, vomiting, diarrhea, constipation, decreased appetite
GLP-1 receptor agonist
Once-daily subcutaneous injection with titration up to 1.8 mg for labeled diabetes use.
Prefilled multi-dose pen.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.